To understand whether IL-17A is also a relevant contributor to CTLA-4 and PD-1 blockade in human melanomas, we used an ex vivo patient-derived tumor fragment (PDTF) model, which has recently demonstrated high predictive capacity for ICI22,23. The gene discussed is PDCD1; the disease is melanoma.